Hospitalization rates of generic metoprolol compared with the original beta-blocker in an epidemiological database study

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 12, 2007, Pages 1298-1307

  Ahrens, Wolfgang ^a   Hagemeier, Constantin ^b   Mühlbauer, Bernd ^c   Pigeot, Iris ^a   Püntmann, Isabel ^c   Reineke, Achim ^a   Steinbach, Monica ^b   Timm, Jürgen ^b  

^a LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^b UNIVERSITY OF BREMEN   (Germany)

^c KLINIKUM BREMEN MITTE   (Germany)

Author keywords

Beta blocker; Cardiovascular diseases; Claims data; Drug prescription; Drug safety; Hospital admission rate; Hypertensive crisis; Myocardial infarction; Pharmaocoepidemiological database; Stroke

Indexed keywords

AGOLOC; ANALGESIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ANTIPYRETIC AGENT; BELOC ZOK; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE PLUS METOPROLOL; GENERIC DRUG; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PERIPHERAL VASODILATING AGENT; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADULT; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG FORMULATION; DRUG SAFETY; FEMALE; GERMANY; HEALTH INSURANCE; HEALTH SERVICES RESEARCH; HEART ARRHYTHMIA; HEART INFARCTION; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS;

ADRENERGIC BETA-ANTAGONISTS; AGED; ARRHYTHMIAS, CARDIAC; ARTHRITIS, RHEUMATOID; DATABASES, FACTUAL; DRUGS, GENERIC; FEMALE; GERMANY; HOSPITALIZATION; HUMANS; HYPERTENSION; INSURANCE CLAIM REVIEW; LOGISTIC MODELS; MALE; METOPROLOL; MIDDLE AGED; MYOCARDIAL INFARCTION; NATIONAL HEALTH PROGRAMS; PRESCRIPTIONS, DRUG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; THROMBOEMBOLISM;

EID: 37349013510     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1494     Document Type: Article

References (6)

1. Tumbull F and Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-1535.
2. Bradley HA, Wiysonge CS, Volmink JA, et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24: 2131-2341.
3. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-1553.
4. Sandberg A, Abrahamsson B, Svenheden A, et al. Steady-state bioavailability and day-to-day variability of a multiple-unit (CR/ZOK) and a single-unit (OROS) delivery system of metoprolol after once-daily dosing. Pharm Res 1993; 10: 28-34.
5. Hoppe UC, Erdmann E. Leitlinien zur Therapie der chronischen Herzinsuffizienz. Z Kardiol 2001; 90: 218-237.
6. SAS (R). Proprietary Software Release 8.2 (TS2MO) Copyright © 1999-2001 by SAS Institute Inc., Cary, NC, USA.